At a glance
The selected evidence now spans animal mechanisms, healthy-participant imaging and two clinical stroke comparisons. These address different questions and have different risks of bias; they should not be pooled as one demonstration of benefit.
Identity & scope
Semax is an ACTH-related seven-residue peptide. This dossier follows the exact catalogue name Semax and does not extend to modified derivatives or certify any supplied material.
What the research shows
- A 24-person experiment reported differences in default-mode-network imaging after Semax compared with placebo.
- Rodent work reported altered serotonin-related measurements and an interaction with experimentally induced dopamine signalling. Semax alone did not change the measured dopamine concentrations in that experiment.
- Stroke studies report neurological or functional improvement, but the accessible abstracts do not establish robust randomization, blinding or separation from concurrent rehabilitation.
Critical interpretation
Clinical reports are relevant, but population matters
The stroke papers add human clinical observations beyond imaging. Their findings concern recovery after neurological injury with concurrent care, not enhancement in healthy people. Treatment allocation and rehabilitation timing need scrutiny before attributing recovery to Semax. These reports are signals for further controlled work rather than evidence that the same effect will occur outside stroke rehabilitation. [3] [4]
A mechanism is not the final outcome
A changed neurotransmitter measure or brain-scan pattern can motivate a mechanism hypothesis without proving a useful cognitive change. The clinical evidence does not remove that distinction: plasma BDNF, functional ratings and everyday cognition are different outcomes. Replication should specify which outcome matters and assess it directly. [2] [4]
Limitations & uncertainties
- An imaging difference is a surrogate measurement, not a demonstrated improvement in memory, attention, work performance or a diagnosed condition.
- The rodent findings cannot determine clinical effectiveness, interactions or safety in people.
- Study preparations do not establish equivalence, absorption, stability, purity or effects of HeartPep catalogue vials or nasal products.
- The clinical stroke reports were assessed from indexed abstracts; the Russian full methods were not reliably available for appraisal.
Open research questions
- Can independently replicated, adequately powered trials demonstrate meaningful cognitive outcomes?
- How do exact peptide identity and formulation affect exposure, reproducibility and longer-term outcomes?
Selected papers & source records
Download bibliography1. Effects of Semax on the Default Mode Network of the Brain (opens in a new tab)
Lebedeva IS et al. (2018). Bull Exp Biol Med. DOI: 10.1007/s10517-018-4234-3 (opens in a new tab) · PMID 30225715
- Design & population
- Resting-state fMRI experiment in 24 healthy adults, with Semax and placebo groups.
- What the study found
- The Semax group showed a larger rostral default-mode-network subcomponent.
- Limits on interpretation
- Small, acute imaging study; no established improvement in practical cognition.
2. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents (opens in a new tab)
Eremin KO et al. (2005). Neurochem Res. DOI: 10.1007/s11064-005-8826-8 (opens in a new tab) · PMID 16362768
- Design & population
- Rodent neurochemistry and behaviour experiments, including an amphetamine challenge.
- What the study found
- Serotonin-metabolite measurements changed. Semax alone did not alter measured dopamine concentrations but enhanced amphetamine-associated responses.
- Limits on interpretation
- Experimental animal endpoints and a drug challenge do not establish cognitive benefit or safety in humans.
3. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study) (opens in a new tab)
Gusev EI et al. (1997). Zh Nevrol Psikhiatr Im S S Korsakova. · PMID 11517472
- Design & population
- Comparative acute-stroke study: 30 Semax-treated patients and 80 conventional-treatment controls.
- What the study found
- The authors reported faster neurological recovery with Semax added to intensive care.
- Limits on interpretation
- Unequal groups; random allocation and blinding are not described in the abstract. Stroke recovery does not establish healthy-person cognitive enhancement.
4. The efficacy of semax in the tretament of patients at different stages of ischemic stroke (opens in a new tab)
Gusev EI et al. (2018). Zh Nevrol Psikhiatr Im S S Korsakova. DOI: 10.17116/jnevro20181183261-68 (opens in a new tab) · PMID 29798983
- Design & population
- Study of 110 stroke-rehabilitation patients, subdivided by rehabilitation timing and Semax exposure.
- What the study found
- The report associated Semax with higher plasma BDNF and improved functional-recovery scores.
- Limits on interpretation
- Allocation and blinding are unclear from the abstract; rehabilitation timing and other treatment complicate causal interpretation. Plasma BDNF is not direct brain measurement.
Search & review scope
Targeted web searches restricted to PubMed, followed by verification of primary-study abstracts and bibliographic records. Initial selection on 8 November was substantively extended on 9 November, with clinical searches, accessible full-text consultation and bounded publication-notice checks.. Checked 9 November 2026.
Selected animal mechanisms, healthy-participant imaging and human stroke-recovery reports, with a deeper clinical pass after the initial review.
Not systematic. Russian clinical full methods could not be reliably assessed. The complete retrieved PubMed record for PMID29798983 showed no linked retraction/erratum section; some other records returned incomplete pages, so publication-status clearance is not comprehensive.
Recorded search terms
- site:pubmed.ncbi.nlm.nih.gov Semax 30225715
- site:pubmed.ncbi.nlm.nih.gov/30225715/
- site:pubmed.ncbi.nlm.nih.gov/16362768/
- site:pubmed.ncbi.nlm.nih.gov "Semax" placebo cognition randomized
- site:pubmed.ncbi.nlm.nih.gov Semax stroke clinical randomized trial
- "Effectiveness of semax" "11517472" retraction
- "The efficacy of semax" "29798983" correction
Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.
Cite this review
HeartPep. Semax: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/us/research/library/semax.
HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.
Buy from HeartPep.com
Laboratory research only. Not for human or veterinary use.